IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v87y2008i3p359-368.html
   My bibliography  Save this article

Healthcare sustainability and the challenges of innovation to biopharmaceuticals in Canada

Author

Listed:
  • Rosenberg-Yunger, Zahava R.S.
  • Daar, Abdallah S.
  • Singer, Peter A.
  • Martin, Douglas K.

Abstract

Governments around the world have focused on issues of sustainability, innovations and priority setting within their health systems. Tension exists between governments' desire to increase biotechnology innovation and the need to address health system sustainability. This commentary will: (1) review government initiatives in biotechnology in health innovation; (2) discuss how innovation, specifically biopharmaceuticals, challenges health system sustainability; and (3) explore how the tension between innovation and sustainability can be addressed using fairness and legitimacy. It is evident that a uni-jurisdictional approach may not be optimal in promoting innovation while ensuring a sustainable health system. Harmonization of biotechnology policies across the federal, provincial, and territorial governments will ensure consistent policies across all branches in order to circumvent the possibility of one governmental branch refusing to reimburse the very innovations other branches are promoting.

Suggested Citation

  • Rosenberg-Yunger, Zahava R.S. & Daar, Abdallah S. & Singer, Peter A. & Martin, Douglas K., 2008. "Healthcare sustainability and the challenges of innovation to biopharmaceuticals in Canada," Health Policy, Elsevier, vol. 87(3), pages 359-368, September.
    • Handle: RePEc:eee:hepoli:v:87:y:2008:i:3:p:359-368
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168-8510(08)00038-9
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Oecd, 2006. "Projecting OECD Health and Long-Term Care Expenditures: What Are the Main Drivers?," OECD Economics Department Working Papers 477, OECD Publishing.
    2. Wiktorowicz, Mary & Deber, Raisa, 1997. "Regulating biotechnology: a rational-political model of policy development," Health Policy, Elsevier, vol. 40(2), pages 115-138, May.
    3. Mitton, Craig R. & McMahon, Meghan & Morgan, Steve & Gibson, Jennifer, 2006. "Centralized drug review processes: Are they fair?," Social Science & Medicine, Elsevier, vol. 63(1), pages 200-211, July.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Lockhart, Michelle & Babar, Zaheer Ud-Din & Garg, Sanjay, 2010. "Evaluation of policies to support drug development in New Zealand," Health Policy, Elsevier, vol. 96(2), pages 108-117, July.
    2. Donglei Song & Yu Xia & Rusi Wang & Hao Xu, 2018. "Using Traditional Chinese Medicine Ideas as a Mechanism to Engage People in Health Awareness," Sustainability, MDPI, vol. 10(8), pages 1-12, August.
    3. Michelle Marie Lockhart & Zaheer-Ud-Din Babar & Christopher Carswell & Sanjay Garg, 2013. "New Zealand’s Drug Development Industry," IJERPH, MDPI, vol. 10(9), pages 1-13, September.
    4. Kylie de Klerk & Favil Singh, 2023. "Does Gender and Cultural Diversity Matter for Sustainability in Healthcare? Evidence from Global Organizations," Sustainability, MDPI, vol. 15(15), pages 1-17, July.
    5. Kessel, Maura & Hannemann-Weber, Henrike & Kratzer, Jan, 2012. "Innovative work behavior in healthcare: The benefit of operational guidelines in the treatment of rare diseases," Health Policy, Elsevier, vol. 105(2), pages 146-153.
    6. Wellman-Labadie, Olivier & Zhou, Youwen, 2010. "The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?," Health Policy, Elsevier, vol. 95(2-3), pages 216-228, May.
    7. Kejia Chu & Ning Zhang & Zhongfei Chen, 2015. "The Efficiency and Its Determinants for China’s Medical Care System: Some Policy Implications for Northeast Asia," Sustainability, MDPI, vol. 7(10), pages 1-20, October.
    8. Wydra, Sven, 2009. "Production and employment impacts of new technologies: analysis for biotechnology," FZID Discussion Papers 08-2009, University of Hohenheim, Center for Research on Innovation and Services (FZID).

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. DE DONDER, Philippe & PESTIEAU, Pierre, 2011. "Private, social and self insurance for long-term care: A political economy analysis," LIDAM Discussion Papers CORE 2011053, Université catholique de Louvain, Center for Operations Research and Econometrics (CORE).
    2. Massimo Baldini & Carlo Mazzaferro & Marcello Morciano, 2008. "Assessing the implications of long-term care policies in Italy: a microsimulation approach," Politica economica, Società editrice il Mulino, issue 1, pages 47-72.
    3. Błażej Łyszczarz, 2018. "Determinanty wydatków na zdrowie w gospodarstwach domowych w Polsce," Gospodarka Narodowa. The Polish Journal of Economics, Warsaw School of Economics, issue 1, pages 137-157.
    4. Torben M. Andersen & Marias H. Gestsson, 2010. "Longevity, Growth and Intergenerational Equity - The Deterministic Case," Economics wp52, Department of Economics, Central bank of Iceland.
    5. repec:dau:papers:123456789/13361 is not listed on IDEAS
    6. de Meijer, Claudine & Koopmanschap, Marc & d' Uva, Teresa Bago & van Doorslaer, Eddy, 2011. "Determinants of long-term care spending: Age, time to death or disability?," Journal of Health Economics, Elsevier, vol. 30(2), pages 425-438, March.
    7. Karolina Lagiewka & Jorge Pinto Antunes, 2011. "European innovation partnership on active and healthy ageing: how is the EU connecting the dots between smart innovation and ageing boom," Review of Applied Socio-Economic Research, Pro Global Science Association, vol. 1(2), pages 95-103, December.
    8. Daron Acemoglu & Amy Finkelstein & Matthew J. Notowidigdo, 2013. "Income and Health Spending: Evidence from Oil Price Shocks," The Review of Economics and Statistics, MIT Press, vol. 95(4), pages 1079-1095, October.
    9. International Monetary Fund, 2006. "Republic of Korea: Selected Issues," IMF Staff Country Reports 2006/381, International Monetary Fund.
    10. Colombier, Carsten, 2012. "Drivers of health care expenditure: Does Baumol's cost disease loom large?," FiFo Discussion Papers - Finanzwissenschaftliche Diskussionsbeiträge 12-5, University of Cologne, FiFo Institute for Public Economics.
    11. M. Collado & Iñigo Iturbe-Ormaetxe, 2010. "Public transfers to the poor: is Europe really much more generous than the United States?," International Tax and Public Finance, Springer;International Institute of Public Finance, vol. 17(6), pages 662-685, December.
    12. repec:aia:ginidp:dp53 is not listed on IDEAS
    13. Elena Nicod, 2017. "Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four Europ," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(6), pages 715-730, July.
    14. Chakroun, Mohamed, 2009. "Health care expenditure and GDP: An international panel smooth transition approach," MPRA Paper 14322, University Library of Munich, Germany.
    15. Morgan, Steven G. & Thomson, Paige A. & Daw, Jamie R. & Friesen, Melissa K., 2013. "Canadian policy makers’ views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers," Health Policy, Elsevier, vol. 112(3), pages 248-254.
    16. Sam Peltzman, 2014. "Socialized medicine and mortality," International Journal of Health Economics and Management, Springer, vol. 14(3), pages 179-205, September.
    17. Whitty, Jennifer A. & Littlejohns, Peter, 2015. "Social values and health priority setting in Australia: An analysis applied to the context of health technology assessment," Health Policy, Elsevier, vol. 119(2), pages 127-136.
    18. Jaromir Cekota & Claudia Trentini, 2012. "Demographic pressures and the sustainability of social security in Emerging Europe and Central Asia," ECE Discussion Papers Series 2012_2, UNECE.
    19. Marc Pomp & Suncica Vujic, 2008. "Rising health spending, new medical technology and the Baumol effect," CPB Discussion Paper 115.rdf, CPB Netherlands Bureau for Economic Policy Analysis.
    20. Walter Ricciardi & Silvia Longhi & Antonio Giulio de Belvis & Roberto Falvo & Tiziana Sabetta & Andrea Silenzi & Pessina Eugenio Anessi, 2012. "Scelte di spesa e trend epidemiologici: un modello di simulazione," PRISMA Economia - Societ? - Lavoro, FrancoAngeli Editore, vol. 2012(3), pages 14-25.
    21. Fan, Victoria Y. & Savedoff, William D., 2014. "The health financing transition: A conceptual framework and empirical evidence," Social Science & Medicine, Elsevier, vol. 105(C), pages 112-121.
    22. Wren, Maev-Ann & FitzPatrick, Aoife, 2020. "How does Irish healthcare expenditure compare internationally?," Research Series, Economic and Social Research Institute (ESRI), number RS114.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:87:y:2008:i:3:p:359-368. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.